These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
287 related articles for article (PubMed ID: 32077525)
1. Validation of a 2-gene mRNA urine test for the detection of ≥GG2 prostate cancer in an opportunistic screening population. Rubio-Briones J; Borque-Fernando A; Esteban LM; Mascarós JM; Ramírez-Backhaus M; Casanova J; Collado A; Mir C; Gómez-Ferrer A; Wong A; Aragón F; Calatrava A; López-Guerrero JA; Groskopf J; Schalken J; Van Criekinge W; Domínguez-Escrig J Prostate; 2020 May; 80(6):500-507. PubMed ID: 32077525 [TBL] [Abstract][Full Text] [Related]
2. PCA3 as a second-line biomarker in a prospective controlled randomized opportunistic prostate cancer screening programme. Rubio-Briones J; Casanova J; Martínez F; Domínguez-Escrig JL; Fernández-Serra A; Dumont R; Ramírez-Backhaus M; Gómez-Ferrer A; Collado A; Rubio L; Molina A; Vanaclocha M; Sala D; Lopez-Guerrero JA Actas Urol Esp; 2017 Jun; 41(5):300-308. PubMed ID: 28342633 [TBL] [Abstract][Full Text] [Related]
3. Detection of High-grade Prostate Cancer Using a Urinary Molecular Biomarker-Based Risk Score. Van Neste L; Hendriks RJ; Dijkstra S; Trooskens G; Cornel EB; Jannink SA; de Jong H; Hessels D; Smit FP; Melchers WJ; Leyten GH; de Reijke TM; Vergunst H; Kil P; Knipscheer BC; Hulsbergen-van de Kaa CA; Mulders PF; van Oort IM; Van Criekinge W; Schalken JA Eur Urol; 2016 Nov; 70(5):740-748. PubMed ID: 27108162 [TBL] [Abstract][Full Text] [Related]
4. Development and Validation of an 18-Gene Urine Test for High-Grade Prostate Cancer. Tosoian JJ; Zhang Y; Xiao L; Xie C; Samora NL; Niknafs YS; Chopra Z; Siddiqui J; Zheng H; Herron G; Vaishampayan N; Robinson HS; Arivoli K; Trock BJ; Ross AE; Morgan TM; Palapattu GS; Salami SS; Kunju LP; Tomlins SA; Sokoll LJ; Chan DW; Srivastava S; Feng Z; Sanda MG; Zheng Y; Wei JT; Chinnaiyan AM; JAMA Oncol; 2024 Jun; 10(6):726-736. PubMed ID: 38635241 [TBL] [Abstract][Full Text] [Related]
5. Optimizing prostate cancer screening; prospective randomized controlled study of the role of PSA and PCA3 testing in a sequential manner in an opportunistic screening program. Rubio-Briones J; Casanova J; Dumont R; Rubio L; Fernandez-Serra A; Casanova-Salas I; Domínguez-Escrig J; Ramírez-Backhaus M; Collado A; Gómez-Ferrer A; Iborra I; Monrós JL; Ricós JV; Solsona E; Salas D; Martínez F; Lopez-Guerrero JA Actas Urol Esp; 2014 May; 38(4):217-23. PubMed ID: 24169211 [TBL] [Abstract][Full Text] [Related]
6. Prediction of prostate cancer risk: the role of prostate volume and digital rectal examination in the ERSPC risk calculators. Roobol MJ; van Vugt HA; Loeb S; Zhu X; Bul M; Bangma CH; van Leenders AG; Steyerberg EW; Schröder FH Eur Urol; 2012 Mar; 61(3):577-83. PubMed ID: 22104592 [TBL] [Abstract][Full Text] [Related]
7. A Prospective Adaptive Utility Trial to Validate Performance of a Novel Urine Exosome Gene Expression Assay to Predict High-grade Prostate Cancer in Patients with Prostate-specific Antigen 2-10ng/ml at Initial Biopsy. McKiernan J; Donovan MJ; Margolis E; Partin A; Carter B; Brown G; Torkler P; Noerholm M; Skog J; Shore N; Andriole G; Thompson I; Carroll P Eur Urol; 2018 Dec; 74(6):731-738. PubMed ID: 30237023 [TBL] [Abstract][Full Text] [Related]
8. Urine TMPRSS2:ERG Plus PCA3 for Individualized Prostate Cancer Risk Assessment. Tomlins SA; Day JR; Lonigro RJ; Hovelson DH; Siddiqui J; Kunju LP; Dunn RL; Meyer S; Hodge P; Groskopf J; Wei JT; Chinnaiyan AM Eur Urol; 2016 Jul; 70(1):45-53. PubMed ID: 25985884 [TBL] [Abstract][Full Text] [Related]
9. A urine-based Exosomal gene expression test stratifies risk of high-grade prostate Cancer in men with prior negative prostate biopsy undergoing repeat biopsy. McKiernan J; Noerholm M; Tadigotla V; Kumar S; Torkler P; Sant G; Alter J; Donovan MJ; Skog J BMC Urol; 2020 Sep; 20(1):138. PubMed ID: 32873277 [TBL] [Abstract][Full Text] [Related]
10. A comparative performance analysis of total prostate-specific antigen, percentage free prostate-specific antigen, prostate-specific antigen velocity and urinary prostate cancer gene 3 in the first, second and third repeat prostate biopsy. Auprich M; Augustin H; Budäus L; Kluth L; Mannweiler S; Shariat SF; Fisch M; Graefen M; Pummer K; Chun FK BJU Int; 2012 Jun; 109(11):1627-35. PubMed ID: 21939492 [TBL] [Abstract][Full Text] [Related]
11. Reflex PCA3 messenger ribonucleic acid testing: validation of postbiopsy urine samples and correlation with prostate biopsy findings in ∼2000 patients. Brown JG; Fulmer JR; Romano J; Pownell J; Rigler W; Wirtshafter A; Sarno M; Shappell SB Urology; 2014 Nov; 84(5):1172-80. PubMed ID: 25443926 [TBL] [Abstract][Full Text] [Related]
12. Development of a Whole-urine, Multiplexed, Next-generation RNA-sequencing Assay for Early Detection of Aggressive Prostate Cancer. Cani AK; Hu K; Liu CJ; Siddiqui J; Zheng Y; Han S; Nallandhighal S; Hovelson DH; Xiao L; Pham T; Eyrich NW; Zheng H; Vince R; Tosoian JJ; Palapattu GS; Morgan TM; Wei JT; Udager AM; Chinnaiyan AM; Tomlins SA; Salami SS Eur Urol Oncol; 2022 Aug; 5(4):430-439. PubMed ID: 33812851 [TBL] [Abstract][Full Text] [Related]
13. Prediction of Prostate Cancer: External Validation of the ERSPC Risk Calculator in a Contemporary Dutch Clinical Cohort. Gayet M; Mannaerts CK; Nieboer D; Beerlage HP; Wijkstra H; Mulders PFA; Roobol MJ Eur Urol Focus; 2018 Mar; 4(2):228-234. PubMed ID: 28753781 [TBL] [Abstract][Full Text] [Related]
14. A molecular signature of PCA3 and ERG exosomal RNA from non-DRE urine is predictive of initial prostate biopsy result. Donovan MJ; Noerholm M; Bentink S; Belzer S; Skog J; O'Neill V; Cochran JS; Brown GA Prostate Cancer Prostatic Dis; 2015 Dec; 18(4):370-5. PubMed ID: 26345389 [TBL] [Abstract][Full Text] [Related]
15. Urinary Prostate Cancer Antigen 3 as a Tumour Marker: Biochemical and Clinical Aspects. Schmid M; Hansen J; Chun FK Adv Exp Med Biol; 2015; 867():277-89. PubMed ID: 26530372 [TBL] [Abstract][Full Text] [Related]
16. The diagnostic value of PCA3 gene-based analysis of urine sediments after digital rectal examination for prostate cancer in a Chinese population. Shen M; Chen W; Yu K; Chen Z; Zhou W; Lin X; Weng Z; Li C; Wu X; Tao Z Exp Mol Pathol; 2011 Feb; 90(1):97-100. PubMed ID: 20970419 [TBL] [Abstract][Full Text] [Related]
17. Combined Clinical Parameters and Multiparametric Magnetic Resonance Imaging for Advanced Risk Modeling of Prostate Cancer-Patient-tailored Risk Stratification Can Reduce Unnecessary Biopsies. Radtke JP; Wiesenfarth M; Kesch C; Freitag MT; Alt CD; Celik K; Distler F; Roth W; Wieczorek K; Stock C; Duensing S; Roethke MC; Teber D; Schlemmer HP; Hohenfellner M; Bonekamp D; Hadaschik BA Eur Urol; 2017 Dec; 72(6):888-896. PubMed ID: 28400169 [TBL] [Abstract][Full Text] [Related]
18. A novel urinary long non-coding RNA transcript improves diagnostic accuracy in patients undergoing prostate biopsy. Zhang W; Ren SC; Shi XL; Liu YW; Zhu YS; Jing TL; Wang FB; Chen R; Xu CL; Wang HQ; Wang HF; Wang Y; Liu B; Li YM; Fang ZY; Guo F; Lu X; Shen D; Gao X; Hou JG; Sun YH Prostate; 2015 May; 75(6):653-61. PubMed ID: 25597901 [TBL] [Abstract][Full Text] [Related]
19. Clinically significant Prostate Cancer diagnosed using a urinary molecular biomarker-based risk score: two case reports. Minnee P; Hessels D; Schalken JA; Van Criekinge W BMC Urol; 2019 Nov; 19(1):124. PubMed ID: 31783839 [TBL] [Abstract][Full Text] [Related]
20. PCA3 sensitivity and specificity for prostate cancer detection in patients with abnormal PSA and/or suspicious digital rectal examination. First Latin American experience. Ramos CG; Valdevenito R; Vergara I; Anabalon P; Sanchez C; Fulla J Urol Oncol; 2013 Nov; 31(8):1522-6. PubMed ID: 22687565 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]